重组人IL-18蛋白-ACROBiosystems百普赛斯

Human IL-18 Protein, premium grade

分子别名（Synonym）

IL-18,Interleukin-18,IL18,IL-1 gamma,IGIF,IL1F4,IL-1F4

表达区间及表达系统（Source）

Human IL-18 Protein, premium grade (IL8-H5114) is expressed from E. coli cells. It contains AA Tyr 37 - Asp 193 (Accession # Q14116-1).

Human IL-18蛋白，premium级别（IL8-H5114），专为临床前阶段设计，具有与GMP级别IL-18蛋白（GMP-L18H16）相同的活性和性能，可实现从临床前开发到临床阶段的无缝过渡。在原材料安全不是首要任务的早期开发阶段，premium产品为GMP产品提供了一种经济高效的替代品。通过在早期开发阶段使用Premium产品，您可以轻松过渡到临床和商业阶段，而无需重新验证原材料和修改制造工艺。

蛋白结构（Molecular Characterization）

This protein carries no "tag".

The protein has a calculated MW of 18.2 kDa. The protein migrates as 17 kDa±3 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE).

内毒素（Endotoxin）

Less than 0.01 EU per μg by the LAL method.

宿主蛋白残留（Host Cell Protein）

<0.5 ng/µg of protein tested by ELISA.

宿主核酸残留（Host Cell DNA）

<0.02 ng/μg of protein tested by qPCR.

无菌（Sterility）

Negative

支原体（Mycoplasma）

Negative.

纯度（Purity）

>95% as determined by SDS-PAGE.

制剂（Formulation）

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

重构方法（Reconstitution）

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

存储（Storage）

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

-20°C to -70°C for 24 months in lyophilized state;

-70°C for 3 months under sterile conditions after reconstitution.

背景（Background）

Interleukin-18 (IL-18) is a potent proinflammatory cytokine that induces interferon-gamma (IFN-gamma) production from Th1 cells, NK cells and activated macrophages, particularly in the presence of IL-12. IL-18 also functions in developmental regulation of T-lymphocyte helper type I cells and in Fas-mediated cytotoxicity. Suppression of IL-18 activity is being investigated for treatment of chronic inflammatory diseases such as Crohn's disease and rheumatoid arthritis. It acts by inducing heterodimerization of the two subunits of its receptor, IL-18RAlpha and IL-18RBeta shows structural similarity to IL-1.